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The antileishmanial efficacies of 2-n-propylquinoline, chimanines B and D, 2-n-pentylquinoline, 2-phe- 
nylquinoline, 2-(3,4-methylenedioxyphenylethyl)quinoline, and two total alkaloidal extracts of Galipea Zongi- 
flora were evaluated in BALB/c mice infected with Leishmania amazonensis or Leishmania venezuelensis. Animals 
were treated for 4 to 6 weeks postinfection with a quinoline by the oral route at 50 mg/kg of body weight twice 
daily for 15 days or by five intralesional injections at  intervals of 4 days with a quinoline at 50 mg/kg of body 
weight. The reference drug, N-methylglucamine antimonate (Glucantime), was administered by subcutaneous 
or intralesional injection (regimens of 14, 28, or 56 mg of pentavalent antimony [Sb"] per kg of body weight 
daily). Twice-daily oral treatment with chimanine B at 50 mgkg resulted in a decrease in lesion weight by 70% 
(P < 0.001) and a decrease in the parasite loads by 95% (P < 0.001). Five injections of chimanine B at  intervals 
of 4 days reduced the lesion weight by 74% and the parasite loads in the lesion by 90% compared with the values 
for the group of untreated mice. Subcutaneous administration of N-methylglucamine antimonate at  28 mg of 
Sb' kg per day for 15 days reduced the parasite burden by 95% (P < 0.001), and five intralesional injections 
at  the same concentration reduced the parasite burden by 96% (P < 0.001). Other 2-substituted quinolines, 
2-n-propylquinoline administered by the oral and intralesional routes, 2-phenylquinoline administered by the 
oral route, 2-II-pentylquinoline administered by intralesional injection, and two total alkaloidal extracts of G. 
Zongijlora administered by the oral route, had intermediate effects. These findings suggest that chimanine B 
may be chosen as a lead molecule in the development of oral therapy against leishmaniasis. 
The increment of in vitro antimony resistance due to inter- 
mittent drug exposure (11, 12, ZO), the isolation of antimony- 
resistant leishmania strains from patients with unresponsive 
cutaneous leishmaniasis (13, 15), and recently, the numerous 
cases of visceral leishmaniasis among patients infected with the 
human immunodeficiency virus (2,3, 5, 19) indicate the neces- 
sity of finding new therapeutic agents for the treatment of the 
leishmaniasis. The great variability observed in the parasite 
strains has been conducive to the assessment of different drugs 
against different parasite strains. For example, in 1993 drugs 
trials in Guatemala indicated that oral azoles proved to be 
more effective than antimonial treatments against cutaneous 
leishmaniasis caused by Leislziiaariia mexicaiia (20), but they 
offered little advantage against cases of disease caused by 
Leishmania bsaziliensis. Currently, specific drugs (pentavalent 
antimony [Sb'], pentamidine, or amphotericin B) used for the 
treatment of leishmaniasis are administered by the parenteral 
route, and the main disadvantages of these treatments are the 
need for an adequate health care infrastructure and the long 
period of patient hospitalization. Oral administration has the 
advantage of reducing treatment-related socioeconomic diffi- 
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culties that are present in areas where the disease is endemic 
and health facilities are lacking. On the basis of the results 
obtained in studies with 2-substituted quinolines (7), the Inte- 
grated Chemotherapy Committee of the Tropical Disease Re- 
search Program of the World Health Organization has estab- 
lished as a priority the ability to provide oral treatment for 
cutaneous leishmaniasis. This treatment would provide a clear 
advantage and cost savings over present drugs for treating 
patients from areas where leishmaniasis is endemic. 
The efficacies of 2-substituted quinolines (lo), isolated from 
a Bolivian medicinal plant, Galipea longifrora Kr of the family 
Rutaceae, in the experimental treatment of cutaneous leish- 
maniasis of the New World (7) have already been reported. We 
have also described their activities in the treatment of experi- 
mental visceral leishmaniasis by the oral and parenteral routes 
(10). Several 2-substituted quinolines, especially 2-substituted 
three-carbon-chain or phenylethyl-chain quinoline alkaloids, 
have been synthesized in our laboratory (17). Oral administra- 
tion of two of these compounds, namely, 2-n-propylquinoline 
and chimanine D, had the same efficacy as the reference anti- 
monial drug. The aims of the present study were to evaluate 
the antileishmanial activities of these 2-substituted quinolines 
against Leislinzania amazonensis and Leislinzania verzezrielensis 
when the drugs were administered by the oral and intralesional 
routes and to select a leading drug for use in clinical trials in 
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FIG. 1. Chemical structures of 2-substituted quinolines. 
veterinary and human medicine. Alkaloidal extracts of stem 
bark and root bark of G. longijlorn, an original Bolivian plant 
used topically and orally to treat cutaneous and mucocutane- 
ous leishmaniasis caused by L, braziliensis, were evaluated as 
well. 
P v í í T Z m s  ANÛ ivlE'iIiûDS 
Chemicals. The 2-substituted quinolines were synthesized as described previ- 
ously (16) or were isolated from the stem bark and leaves of G. longifora by 
fractionation and purification, monitored by bioassay, as described previously (8, 
11). Physical and spectral data (proton and 13carbon nuclear magnetic resonance 
and mass spectrometry) were used to control the purities of the 2-substituted 
quinolines. The structures of these compounds are shown in Fig. 1. N-Methyl- 
glucamine antimonate (Glucantime), equivalent to 0.28 mg of Sb" per ml, was 
purchased from Rhône-Poulenc, Paris, France. 
Experimental animals. Female and male BALB/c mice were supplied by the 
IFFA-CREDO, Lyon, France, and were bred at the Instituto de Investigaciones 
en Ciencias de la Salud, Asuncion, Paraguay. Golden hamsters (Mesocrifus art- 
rafrcs) were used to maintain the parasites. 
Infection. L. amazonensis MHOMIIFLAIBRI67IPH8 and L. venexelensis 
MHOM/VE/74PM-H3 were used. These strains were obtained from the Insti- 
tuto Boliviano de Biologia de Altura (La Paz, Bolivia) and were identified by 
isoenzyme analysis. All strains were maintained by passage eveIy 6 to 8 weeks in 
hamsters. BALB/c mice (n = 8) were inoculated in the right hind footpad with 
2 X lo6 amastigotes obtained from donor hamsters. The parasites were delivered 
in 100 pl of phosphate-buffered saline (PBS). Disease progression was monitored 
by the measurement of lesion diameters weekly for up to 7 to 12 weeks. 
Drug treatment. In all experiments, treatment was initiated 4 or 5 weeks after 
inoculation, when the infection was well established and lesions were obvious. 
Two days before administration of drug, the mice were randomly divided into 
groups of eight. N-Methylglucamine antimonate was dissolved in 50 p1 of PBS 
and was administered to the BALB/c mice in regimens of 56,28, or 14 mg of Sb" 
per kg of body weight daily for 15 days by the subcutaneous route or by five 
intralesional injections of 28 mg of Sb" per kg of body weight in the infected 
footpad at intervals of 5 days. The 2-substituted quinolines or total alkaloidal 
extracts of G. longifora root bark or stem bark were tested at a dose of 50 mgkg 
of body weight and were made up in 50 p1 of PBS-5 p1 of polysorbate (Tween 
80; OSI, Elancourt, France). The drugs were administered twice daily by the oral 
route for 15 days or five times by intralesional injection into the infected footpad 
at intervals of 5 days. The untreated group received 50 pl of PBS and 5 p1 of 
Tween 80 daily. 
Effect of treatment. The animals were sacrificed 1 week after the cessation of 
treatments to assess parasitological loads in the infected footpad. Briefly, the 
mice were killed, and the lesions of the infected footpad were excised, weighed, 
and homogenized in a tissue glass grinder and then homogenized in 5 ml of 
RF'MI 1640 (GIBCO, Paris, France) tissue culture medium supplemented with 
10% fetal calf serum, 1 ml of glutamine (29.4 pg/mk GIBCO), penicillin (100 
U/ml), and streptomycin (100 pg/ml). After 7 days of incubation at 27T, the 
plates (25 cm'; Falcon T) were examinedwith an inverted microscope (Olympus) 
at a magnification of X400. The number of parasites per gram in the lesion was 
calculated by the following equation: parasite burden = geometric mean of the 
number of parasites in each duplicate/(number of microscope field counted X 
weight of lesion X hemocytometer correction factor [25,000]). Also, smears were 
prepared from the infected lesions, k e d  with absolute methanol, and stained 
with Giemsa (OSI), and amastigotes were counted with an inverted microscope 
at a magnification of X400 (6, 14). Five hundred cell nuclei from each animal 
TABLE 1. Inhibitory effects of treatments with N-methylglucamine antimonate by the subcutaneous a n d  intralesional routes 
and 2-n-propylquinoline on L. venezuelensis-infected BAL,B/c mice 
Drug (dosage) Route of ad- Lesion wt (9) % Suppression 5% Suppression Of Mean no' Of ministration (mean 2 SD)a of lesion wt parasite burden parasites in 
in lesion lesion/g 
None (control) 0.094 2 0.020 1.6 x 107 
N-Methylglucamine antimonate (56 mg of Sb' for 15 days) Subcutaneous 0.020 f 0.013 -79b -88' 1.9 x lo6 
N-Methylglucamine antimonate (56 mg of Sb" for 15 days) Intralesional 0.008 2 0.013 -91' -96' 5.6 x 105 
2-n-Propylquinoline (50 mg twice daily for 15 days) Oral 0.053 2 0.022 - 44" -7T 3.6 X 10' 
2-n-Propylquinoline (50 mg for 5 days) Intralesional 0.096 2 0.052 +2 -81' 3.0 X lo6 
Values represent the means t- standard deviations for eight mice per group. ' P < 0.001 for treated versus control mice; values were confirmed to be 10.05 by ANOVA and Student's t test. 
P < 0.01 for treated versus control mice; values were confirmed to be <0.05 by ANOVA and Student's i test. 
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TABLE 2. Effects of treatments with N-methylglucamine antimonate by the  subcutaneous route and with 2-it-propylquinoline, chimanine B, 
2-phenylquinoline, chimanine D, and  2-n-pentylquinoline by the oral o r  intralesional route  on L. umuzoizensis-infected BALB/c mice 
Drug (dosage) 
None (control)" 
N-Methylglucamine antimonate (28 mg of Sb" for 15 days)" 
N-Methylglucamine antimonate (14 mg of Sb" for 15 days) 
2-n-Propylquinoline (50 mg twice daily for 15 days) 
2-iz-Propylquinoline (50 mg for 5 days 
Chimanine B (50 mg twice daily for 15 days)" 
Chimanine B (50 mg for 5 days)" 
2-Phenylquinoline (50 mg twice daily for 15 days)" 
2-Phenylquinoline (50 mg for 5 days)" 
Chimanine D (50 mg twice daily for 7 days)" 
Chimanine D (50 mg for 2 days)" 
2-n-Pentylquinoline (50 mg twice daily for 15 days)" 
2-n-Pentylquinoline (50 mg for 5 days)" 
Route of Lesion wt (g) 
administration (mean ? SD) 
Subcutaneous 
Subcutaneous 
Oral 
Intralesional 
Oral 
Intralesional 
Oral 
Intralesional 
Oral 
Intralesional 
Oral 
Intralesional 
0.096 rt 0.042 
0.010 5 0.013 
0.085 f 0.031 
0.055 t 0.018 
0.013 rt 0.013 
0.029 -1- 0.016 
0.025 f 0.009 
0.031 t 0.016 
0.086 f 0.036 
0.061 5 0.040 
0.082 f 0.056 
0.077 rt 0.018 
0.033 ? 0.036 
-90' 
-11 
- 43d 
-86" 
-70' 
-74' 
-68' 
- 10 
-36 
- 15 
-20 
-66f 
~ 
-95" 
-17 
-77d 
-96' 
-95' 
-90' 
-94' 
- 10 
-52 
+13 - 45 
- 84" 
~ 
8.3 X loG 
6.9 X lo6 
1.9 X lo6 
4.3 x 105' 
3.0 x 105 
4.3 x 105 
8.3 x 105 
4.7 x 105 
7.9 x loG 
4.0 X lo6 
9.4 x loG 
4.6 X lo6 
1.3 X lofi 
a Values represent the means ? standard deviations for two pooled experiments or for 16 mice per group. " Values represent the means ? standard deviations for one experiment with eight mice per group. 
P < 0.001 for treated versus control mice; values were confirmed to be <0.05 by ANOVA and Student's f test. 
P < 0.002 for treated versus control mice; values were confirmed to he <0.05 by ANOVA and Student's f test. 
e P < 0.01 for treated versus control mice; values were confirmed to be <0.05 by ANOVA and Student's t test. 
fP < 0.05 for treated versus control mice. 
were examined under oil immersion. A good correlation (R = 0.835) was found 
between the two methods of determining the parasite burden, and data from first 
method are presented in Tables 1 to 4. 
A corrected parasite suppression index was calculated by the following for- 
mula: 
Mean number of parasites in (or weight of) treated mice X 100 
Mean number parasites in (or weight of) untreated mice - 100 
Statistical analysis. The mean and standard deviation were calculated by using 
Microsoft EXCEL software. Comparisons of parasite suppression in the infected 
footpads of the untreated and drug-treated groups were done by analysis of 
variance (ANOVA) and Student's t test. Data were considered statistically sig- 
nificant at P < 0.05. 
RESULTS 
Treatment with 2-n-propylquinoline. Table 1 presents the 
results of the effect of 2-i~propylquinoline in vivo on lesion 
weight and parasite numbers in L. veizezueletzsis-infected ßALß/c 
mice. In this experiment 2-n-propylquinoline was administered 
by the oral or intralesional route and N-metliylglucamine was 
administered by the subcutaneous or intralesional route. N- 
Methylglucamine produced a significant reduction in the num- 
ber of parasites in the lesion: by 88% (P < 0.001) and 96% 
(P < 0.001) by the subcutaneous and intralesional routes, re- 
spectively. Treatment with 2-iz-propylquinoline suppressed le- 
sional parasites by 17% (€' < 0.05) and 81% (P < 0.05) the by 
the oral and intralesional routes, respectively. 
Two independent experiments were performed in order 
to determine the effects of twice-daily oral treatment with 
2-iz-propylquinoline for 15 days on L. anzazoneiisis-infected 
BAL,B/C mice. Table 2 presents the results of these experi- 
ments and includes the effect of 2-n-propylquinoline when it 
was administered orally once daily or by five intralesional in- 
jections of 50 mgkg at intervals of 4 days. In all the experi- 
ments, twice-daily treatment with 2-n-propylquinoline pro- 
duced a significant suppression (P < 0.002) of the parasite 
burden in the lesion. Intralesional treatment with 2-n-propy- 
lquinoline was efficient as well; in this case, the parasite burden 
in the infected footpads decreased by 96% (P < 0.001) com- 
pared with the burden in the footpads of untreated mice. In 
BALß/c mice treated with 15 subcutaneous injections of N- 
methylglucamine, parasites were suppressed by 95% (P < 
0.001) compared with the parasite burden in untreated mice. 
Treatment with chimanine B. The effect of treatment of 
ßALB/c mice infected with L. amazoraeizsis with N-methylglu- 
camine or chimanine ß by the oral or intralesional route is 
presented in Fig. 2. The lesions in treated mice did not increase 
in size during the first 3 weeks. In contrast, untreated mice had 
rapidly enlarging lesions. Twice-daily oral treatment with chi- 
manine ß at 50 mg per kg of body weight resulted in a signif- 
icant effect (Table 2). A decrease in the lesion weight (70%; 
P < 0.001) and a decrease in the parasite burden of the in- 
fected footpads (95%; P < 0.001) were observed. The efficacy 
of this quinoline was similar to that of the regimen of the 
antimonial agent at 28 mdkg of body weight per day for 15 
days, which reduced the lesion weight by 90% (P < 0.001) and 
the parasite burden by 95% (P < 0.001). Nevertheless, once- 
daily oral treatment with chimanine ß at 50 mgkg was not as 
4 
3,5 T - 
- 
- 
O 1 2 3 4 5 6 7  
Weeks after infection 
FIG. 2. Effects of treatments with N-methylglucamine antimonate (28 mg of 
Sb" per kg per day) (A) and chimanine B administered orally at 50 mg/kg twice 
daily for 15 days (O) and intralesionally for five injections at 50 mg/kg at intervals 
of 4 days (*) during the course of infection of BALB/c mice with L. amazorzensis 
(O, untreated mice). Each point represents the mean t standard deviation of the 
mean difference in size between infected and uninfected footpads for 16 un- 
treated mice, 16 mice treated orally with chimanine B, and 8 mice treated 
intralesionally with chimanine B. 
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FIG. 3. Effects of treatments with N-methylglucamine antimonate (28 mg of 
Sb" per kg per day) and 2-phenylquinoline administered orally at 50 mgkg twice 
daily for 15 days and intralesionally for 5 injections at 50 mglkg at intervals of 4 
days during the course of infection of BALB/c mice with L. ninnzoitensis. Each 
point represents the mean 2 standard deviation of the mean difference in lesion 
size between infected and uninfected footpads for 16 untreated mice, 16 mice 
treated orally with 2-phenylquinoline, and 8 mice treated intralesionally with 
2-phenylquinoline. 
effective as twice-daily oral administration. Subcutaneous 
treatment with the antimonial agent at 14 mg/kg of body 
weight per day for 15 days had no effect (reduction of 11% of 
lesion weight and 17% of parasite burden). When chimanine B 
was administered by five intralesional injections, it reduced the 
parasite load by 90% (P < 0.01). 
Treatment with 2-phenylquinoline. 2-Phenylquinoline is the 
major quinoline alkaloid of G. Zongijlora, a Bolivian plant used 
as treatment for cutaneous leishmaniasis. In previous experi- 
ments (8), 2-phenylquinoline had no effect when it was admin- 
istered by subcutaneous injection. However, treatment with 
2-phenylquinoline administered orally at 50 mg/kg twice daily 
for 15 days decreased the lesion weight by 68% (P < 0.001) and 
suppressed the parasite burden by 94% (P < 0.001) (Table 2). 
Five intralesional injections of 2-phenylquinoline at 50 mg/kg 
at intervals of 4 days did not suppress the parasite burden. The 
lesions of animals receiving 2-phenylquinoline orally twice 
daily increased slightly in size (Fig. 3). 
Treatment with miscellaneous 2-substituted quinolines. No 
significant difference was observed between untreated BALB/c 
mice and mice treated orally or intralesionally with various 
2-substituted quinolines, including skimmianine and 2-(3,4- 
methylenedioxyphenylethy1)quinoline (Table 3). However, on 
both occasions, intralesional treatment with 2-n-pentylquino- 
line or twice-daily oral treatment with chimanine D (Table 2) 
for 5 days resulted in parasite loads in the infected footpads 
that were decreased by 84% (P < 0.002) and 52% (not signif- 
icant), respectively. Oral or intralesional combined treatment, 
including a mixture containing equal parts of 2-phenylquino- 
line and 2-n-pentylquinoline, did not have a leishmanicidal 
effect on L. anzazonensis. 
Treatment with total alkaloidal extracts of G. ZongiJloru. 
Extracts of stem bark or root bark of G. longijlora were ad- 
ministered twice daily by the oral route for 15 days at 50 mgkg 
or by five intralesional injections of 50 m&g at intervals of 4 
days. The results are presented in Table 4. Oral treatment with 
root bark extract reduced the weights of the lesions by 70% 
(P < 0.001) and the parasite load by 95% (P < 0.001). Intrale- 
sional treatment reduced the lesion weights and parasites loads 
by 46% (P < 0.001) and 96% (P < O.OOl), respectively. In- 
tralesional treatment with stem bark extract decreased the 
lesion weight by 24% and decreased the parasite loads in the 
infected footpads by 99% (P < 0.001). Oral treatment did not 
show the same efficacy, reducing the parasite load by only 49% 
(P < 0.05). 
DISCUSSION 
The results indicate that twice-daily oral treatment with chi- 
manine B, 2-n-propylquinoline, or 2-phenylquinoline at 50 
mg/kg for 15 days produces the same effect as treatment with 
the classical antimonial drug (N-methylglucamine antimonate) 
in L. amazonensis-infected BALB/c mice. The leishmanicidal 
activities of chimanine B and 2-n-propylquinoline adminis- 
tered to experimentally infected mice by the subcutaneous 
route at 100 mg/kg were described previously (7). While com- 
plete cure did not occur, animals treated with these quinolines 
had small lesions and low i. amazonensis loads (3 X 16' i o  4 X 
lo5) in the infected footpads. In contrast, we have observed the 
inexorable development of disease in untreated mice (infected 
with lo7 amastigotes). Chimanine B and 2-n-propylquinoline 
are two compounds with a propyl chain for which the synthetic 
preparation process does not present any inconvenience (17). 
The reduced toxicities of these products will facilitate treat- 
ment for longer durations, perhaps with three daily adminis- 
trations for 30 or 60 days. We were surprised by the results 
obtained with oral 2-phenylquinoline. This quinoline is the 
major alkaloid in the stem bark or root bark of G. lOl7giflOrU. 
Each kilogram of dried stem bark and root bark contains 15 
and 25 g of this quinoline, respectively. The extraction of the 
compound is very easy, and it could potentially be used to treat 
those suffering from leishmaniasis in developing countries. The 
TABLE 3. Effects of t reatments  with N-methylglucamine antimonate by the subcutaneous route  and skimmianine and  
2-(3,4-methylenedioxyphenylethyl)quinoline administered by t h e  intralesional or oral  route  
o n  L. amazonensis-infected BALBlc mice 
Drug (dosage) Route of Lesion wt (g) % Suppression % parasite Suppression burden Of Mean sites no' in lesion/g Of para- 
(lo6) administration (mean 2 SD)" of lesion wtb in 
None (control) 0.046 2 0.015 5.6 
2-(3,4-Methylenedioxyphenylethyl)quinoline (50 mg twice daily Oral 0.045 t 0.018 -2 -29 4.0 
2-(3,4-Methylenedioxyphenylethyl)quinoline (50 mg for 5 days) Intralesional 0.048 t 0.018 f 4  -14 4.8 
Skimmianine (50 mrr for 5 davsl Intralesional 0.049 f 0.025 +7 -1 5.2 
N-Methylglucamine antimonate (14 mg of Sb" for 15 days) Subcutaneous 0.040 -C- 0.0312 -13 -16 4.7 
for 15 days) 
Skimmianine (50 mg twice daily for 15 days) Oral 0.039 -t- 0.029 -15 - 12 4.9 
Values represent the means 2 standard deviation for eight mice per group. 
Treated versus control mice. 
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TABLE 4. Effect of treatments with alkaloidal extracts of root bark or stem bark of G. IoizgifIora administered by 
the intralesional or oral route on L. unzuzoneivis-infected BALB/c mice 
Drug (dosage) Route of ad- Lesion wt (8) % Suppression ?6 Suppression Of Mean no' Of ministration (mean 2 SD) of lesion wf parasite 'Ilrden parasites in 
in lesion" lesion/g 
None (control) 0.127 2 0.064 1.0 x 107 
Alkaloid extract of root bark of G. loizgifZora (50 mg twice daily Oral 0.038 2 0.022 -70' - 95' 5.3 x 105 
Alkaloid extract of root bark of G. lorzgifora (50 mg for 5 days) Intralesional 0.068 2 0.019 -46' - 96" 3.7 x 105 
Alkaloid extract of stem bark of G. loizgipora (50 mg for 5 days) Intralesional 0.097 2 0.036 - 24 -99' 1.1 x 105 
for 15 days) 
Alkaloid extract of stem bark of G. 1oiigifZor.a (50 mg twice daily Oral 0.064 ? 0.026 -50' -49" 5.1 X loG 
for 15 days) 
a Values represent the means h standard deviations for one experiment with eight mice per group. 
P < 0.001 for treated versus control mice; values were confirmed to be <0.05 by ANOVA and Student's t test. 
P < 0.05 for treated versus control mice: values were confirmed to be <0.05 by ANOVA and Student's t test. 
activities of extracts of G. longiflora stem bark and root bark 
demonstrate that this folk remedy for cutaneous leishmaniasis 
is effective. The other major 2-substituted quinoline, 2-ia-pen- 
tylquinoline, did not show any activity when it was adminis- 
tered by the oral route, but it had significant activity when it 
was administered by intralesional injection. We cannot explain 
these variable leishmanicidal activities because the modes of 
action of these compounds are unknown. However, it seems 
that the active 2-substituted quinolines, chimanine B or 2-n- 
propylquinoline, have good absorption (they are oily com- 
pounds) and are metabolized at low levels. L. amazonensis- 
infected BALB/c mice are not the perfect model for testing the 
effectiveness of compounds against leishmaniasis, but the pro- 
duction of high numbers of parasites at the sight of the lesion 
allows for the evaluation of new drugs (1, 4, 18). 
We conclude that of the 2-substituted quinolines tested, 
chimanine B is the more effective compound and is the lead 
molecule in this group of natural chemical compounds. The 
results obtained in the present study are sufficiently encourag- 
ing to continue the development of 2-substituted quinolines as 
antileishmanial drugs, especially chimanine B, 2-E-propyl- 
quinoline, and perhaps 2-phenylquinoline, and pharmacoki- 
netic and toxicological studies with these compounds are war- 
ranted. In the coming months, clinical trials of oral treatments 
with chimanine B and 2-iz-propylyuinoline will be in progress 
in Bolivia with the support of the Bolivian Ministery of Health 
and the World Health Organization. 
The present study is an example of the development of 
antileishmanial products based on ethnomedical information 
obtained from populations which use traditional remedies with 
a long history of efficacy and tolerance in humans (16). 
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